Y-mAbs Therapeutics Inc
YMAB
Company Profile
Business description
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
Contact
230 Park Avenue
Suite 3350
New YorkNY10169
USAT: +1 646 885-8505
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
100
Stocks News & Analysis
stocks
Is CSL undervalued after earnings season wobble?
The ASX's biggest healthcare name saw its shares fall after reporting first-half results.
stocks
After earnings is Apple stock a buy, sell or fairly valued?
Our thoughts on Apple's stock amid slowing iPhone sales but high services revenue.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,799.60 | 48.00 | 0.55% |
| CAC 40 | 8,046.82 | 17.92 | 0.22% |
| DAX 40 | 22,105.61 | 67.78 | 0.31% |
| Dow JONES (US) | 44,593.65 | 123.24 | 0.28% |
| FTSE 100 | 8,784.57 | 7.18 | 0.08% |
| HKSE | 21,857.92 | 563.06 | 2.64% |
| NASDAQ | 19,643.86 | 70.41 | -0.36% |
| Nikkei 225 | 38,963.70 | 162.53 | 0.42% |
| NZX 50 Index | 12,913.95 | 3.50 | -0.03% |
| S&P 500 | 6,068.50 | 2.06 | 0.03% |
| S&P/ASX 200 | 8,535.30 | 51.30 | 0.60% |
| SSE Composite Index | 3,346.39 | 28.33 | 0.85% |